Pivotal to Support Hyperimmune COVID-19 Plasma Trial

To provide clinical research services in study evaluating the efficacy and safety of plasma from COVID-19 convalescent patients compared to standard treatment.

By: Contract Pharma

Contract Pharma Staff

Pivotal, a European CRO, has been contracted to provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma, obtained from cured and convalescent COVID-19 patients, in the treatment of hospitalized patients with COVID-19. This study will use the plasma extracted from approximately 200 convalescent patients with COVID-19 to treat patients in the acute phase of this disease compared with standard treatment. The trial will be carried ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters